For generations, Fox Chase Cancer Center—Temple Health and the American Association for Cancer Research (AACR) have shared a commitment to advancing cancer research and translating scientific discoveries into better outcomes for patients.
That longstanding relationship was the foundation for an October 8 visit to Fox Chase by AACR Chief Executive Officer Margaret Foti, PhD, MD (h.c.), who met with Fox Chase leadership, researchers, and community representatives to explore opportunities for deeper collaboration.
The visit offered an opportunity to showcase Fox Chase's scientific expertise while identifying ways to expand faculty engagement with AACR, strengthen the cancer research workforce, and advance shared priorities, including cancer prevention, early detection, and greater participation in clinical trials.
"Fox Chase and AACR have a remarkable, shared history, and that relationship continues to be an important part of who we are as a cancer center," said Robert G. Uzzo, MD, MBA, President and CEO of Fox Chase. "Marge Foti has played an extraordinary role in advancing cancer research, and we were delighted to welcome her to Fox Chase. This was an opportunity not only to celebrate our longstanding connections, but also to explore how our researchers can help shape the future of cancer science."
During a presentation to Fox Chase faculty and staff, Foti highlighted AACR's growth into an international organization of more than 67,000 members and discussed emerging priorities, including artificial intelligence, cancer vaccines, survivorship, and the importance of developing the next generation of cancer researchers.
She also reflected on Fox Chase's contributions to cancer research and its longstanding connections to AACR, recognizing the institution's history of scientific discovery and the work of its current faculty.
An important focus of the visit was the need to ensure that advances in cancer research reach patients and communities that have historically experienced disparities in cancer care. Foti met with community representatives to discuss patient advocacy, building trust in science, and the importance of incorporating community perspectives into research.
These priorities closely align with the work of Robert A. Winn, MD, Cancer Center Director at Fox Chase, whose efforts to broaden participation in clinical trials have helped shape national initiatives, including the AACR's Robert A. Winn Excellence in Clinical Trials Award Program.
"Scientific discovery is only part of our responsibility. We also have to make sure that discoveries translate into meaningful improvements in people's lives, particularly in communities that have not always benefited equally from advances in cancer care," said Winn. "AACR has been an important partner in that work, and Marge understands that engaging communities, developing young scientists, and expanding access to clinical trials are essential to making progress against cancer. We see tremendous opportunities to build on that shared commitment."
Foti also had an opportunity to learn more about research underway at Fox Chase. During an executive roundtable with scientific leadership, discussions focused on opportunities for Fox Chase faculty to contribute their expertise to AACR committees, scientific programs, and emerging research initiatives.
Foti encouraged researchers to become more involved in AACR's activities and to share ideas that could help inform the organization's future direction.
"I just appreciate learning about what you're doing, because it helps me," Foti told participants, noting the opportunities to connect researchers with AACR committees and scientific initiatives.
The discussions underscored the value of a relationship that has connected Fox Chase scientists with the broader cancer research community for decades, and the potential for an even stronger partnership as both organizations work to accelerate discovery, develop future scientific leaders, and bring the benefits of cancer research to more people.